Evidence map›Paper›PMID 39474602›Full record

ArticleMolecular therapy. Oncology2024

CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity.

John F Imbery, Celina Wiik, Julia Heinzelbecker, Jenny K Jebsen, Mia K Dobbing, Nunzio Bottini, Stephanie M Stanford, Ludvig A Munthe, Geir E Tjønnfjord, Anders Tveita and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

John F ImberyDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Celina WiikDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Julia HeinzelbeckerKG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, and Department of Immunology, Oslo University Hospital, Oslo, Norway.
Jenny K JebsenDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Mia K DobbingDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Nunzio BottiniKao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Stephanie M StanfordDivision of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Ludvig A MuntheKG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, and Department of Immunology, Oslo University Hospital, Oslo, Norway.
Geir E TjønnfjordKG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, and Department of Immunology, Oslo University Hospital, Oslo, Norway.
Anders TveitaPrecision Immunotherapy Alliance (PRIMA), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Peter SzodorayDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Britt NakkenDepartment of Immunology, Oslo University Hospital, Oslo, Norway.

Funding

Role of PTPN2 in rheumatoid arthritisR01AI148073 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOTTINI, NUNZIO · 2019 to 2023
$2.7M
NIAID NIH HHS R01 AI148073
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) growth is dependent on both B cell receptor (BCR) signaling and signals from microenvironmental T helper (Th) cells. We previously described a mechanism where Th cells enhance BCR signaling and proliferation through CD45 phosphatase activity regulation via galectin-1 and CD43. The CLL negative prognostic indicator CD38 is linked to BCR signaling and proliferation, with its expression induced by Th cells. Here, we explore a link between CD38 and CD45 phosphatase activity regulation using patient-derived material in a Th-CLL cell co-culture model. Results demonstrate CD43 and galectin-1 are co-expressed with CD38, defining proliferative CLL cells with augmented CD45 activity. CD38 enzymatic and receptor inhibition regulated CD43 and galectin-1 expression, CD45 activity

Indexed as

BCR signalingCD38CD43CD45chronic lymphocytic leukemiaCLLgalectin-1MT: Regular IssueproliferationTh cells

Identifiers

PMID39474602
PMCPMC11519781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.